<DOC>
	<DOCNO>NCT01575301</DOCNO>
	<brief_summary>The purpose study collect cohort patient treat GLP-1R Agonists ass phenotypic , genetic genomic biomarkers glycaemic response agent .</brief_summary>
	<brief_title>DIabetes REsearCh Patient sTratification ( DIRECT ) : GLP-1R Agonists</brief_title>
	<detailed_description>To develop cohort patient treat GLP-1 R Agonists phenotyped baseline 6 month follow determine clinical , image biomarker predictor glycaemic response GLP-1R Agonists . The hypothesis one , combination , biomarkers associate glycaemic response GLP-1R Agonists . The primary outcome therefore HbA1c reduction 6 month GLP-1R A treatment . This cohort study 800 patient treat either exenatide liraglutide 6 month , carry 4 UK centre .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients Type 2 diabetes clinical decision make commence GLP1R agonist Either : 1 . On combination oral hypoglycaemic agent 2 . On Insulin ( +/ oral hypoglycaemic agent ) HbA1c ≥7.5 % ( 58mmol/mol ) HbA1c &lt; 12 % ( 108mmol/mol ) White European Age ≥ 18 &lt; 80 Type 1 diabetes HbA1c &lt; 7.5 % ( 58 mmol/mol ) HbA1c ≥ 12 % ( 108 mmol/mol ) Pregnancy lactation Any significant medical reason exclusion determine investigator Inability consent Participating CTIMP study period within 30 day prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>GLP-1R agonist</keyword>
	<keyword>biomarker</keyword>
</DOC>